Mendeley  

Zotero  

Habibi M A, Anjomshoa A, Sadeghi-Naini M, Ghodsi Z, Berchi Kankam S, Razavi E, et al et al . Histopathological Effects of the Intrathecal Chondroitinase ABC Administration in Spinal Cord Injured Rats: A Systematic Review. BCN 2026; 17 (1) :1-24
URL: http://bcn.iums.ac.ir/article-1-2744-fa.html

Introduction: Chondroitinase ABC (ChABC) has been considered a potential treatment for spinal cord injury (SCI). We aim to identify and evaluate the histopathological effects of intrathecal ChABC administration in SCI rat models. 
Methods: We searched PubMed/MEDLINE, Scopus, Web of Science, Embase, and Cochrane Library for studies published from the inception of each database until November 22, 2022.
Results: Of 3857 screened citations, 17 studies met eligibility criteria and were entered into the qualitative analysis. Sixteen studies were of high quality, and one study was of medium quality. The four main rat strains used in studies were Sprague-Dawley, Wistar, Lister hooded, and Long-Evans. ChABC treatment phases were considered acute (within 24 hours after injury), subacute (5 or 7 days after injury), or chronic (4 or 6 weeks after injury). Accordingly, ChABC administration in the acute phase of injury significantly reduced cyst formation and promoted tissue preservation and sensory neuron plasticity. Regardless of the treatment phase, ChABC administration significantly promoted serotonergic and corticospinal fiber plasticity. Nine of the 14 studies reporting on functional outcomes found that ChABC administration, alone or in combination with other treatments, including rehabilitation, improved motor function. 
Conclusion: The specification of anatomical changes associated with ChABC treatment can explain the functional improvements reported with its use in SCI. The limited studies on more clinically relevant contusion and compression injury models warrant further investigation of these models and alternative treatment phases.